Athira Pharma Inc Stock News

Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025

Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.

ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025

Athira Pharma said on Tuesday its investigative drug failed to meet the main goal in a mid-to-late stage trial in patients with mild-to-moderate Alzheimer's disease.

LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23)

Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease targeted for September 2024 Phase 2/3 LIFT-AD data to be presented in an oral presentation at CTAD in October 2024 Phase 1 clinical trial of ATH-1105 underway for the potential treatment of amyotrophic lateral sclerosis (ALS) BOTHELL, Wash., Aug. 01, 202...

Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients